Research Article
Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast
Table 1
Serum levels of IGFBP-2 by case-control status and levels of other variables.
| | | | Mean serum IGFBP-2 (IQR) in cases | | Mean serum IGFBP-2 (IQR) in controls |
| | All subjects | 275 | 211.4 (147.9–315.7) | 275 | 225.0 (149.7–347.9) | | BMI | | | | | | Normal (<25 kg/m2) | 90 | 315.5 (193.1–427.6) | 79 | 320.5 (187.9–433.0) | | Overweight/obese (≥25 kg/m2) | 184 | 176.7 (135.3–257.4) | 195 | 198.6 (137.4–297.3) | | | | | | < 0.001 | | HT Use | | | | | | Nonusers of HT | 139 | 244.7 (147.1–341.0) | 160 | 241.5 (174.8–376.4) | | Unopposed estrogen | 62 | 191.9 (143.7–315.4) | 59 | 158.3 (127.0–311.4) | | Progestin + estrogen | 74 | 187.4 (148.8–262.9) | 56 | 191.9 (140.9–296.7) | | | | = 0.04 | | = 0.004 | | History of diabetes | | | | | | No | 259 | 219.6 (148.5–317.3) | 258 | 229.8 (152.9–360.1) | | Yes | 16 | 185.0 (124.8–273.1) | 17 | 157.7 (139.6–193.1) | | | | = 0.33 | | = 0.01 | | Age at baseline | | | | | | <Median (62 yrs) | 140 | 189.5 (136.5–284.1) | 137 | 187.9 (136.8–281.7) | | ≥Median (62 yrs) | 135 | 246.3 (153.0–339.6) | 138 | 277.9 (180.4–400.0) | | | | = 0.01 | | < 0.001 | | Race | | | | | | White | 238 | 219.9 (149.5–328.5) | 238 | 232.0 (154.7–362.8) | | Black | 22 | 145.6 (110.2–264.7) | 22 | 181.1 (126.7–246.5) | | Other | 15 | 235.7 (153.0–283.5) | 15 | 187.6 (145.8–347.9) | | | | = 0.08 | | = 0.05 | | Smoking status | | | | | | Never | 134 | 214.8 (150.1–338.7) | 149 | 235.8 (156.5–364.4) | | Ever | 141 | 211.4 (144.0–309.5) | 126 | 205.0 (147.4–311.4) | | | | = 0.40 | | = 0.24 |
|
|
